📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
84 announcements match the current filters (relevance ≥ 5).
EMA Approves Lupin's NaMuscla Expansion for Pediatric Use with New Strengths
Lupin has received European Medicines Agency (EMA) approval to expand the indication of NaMuscla to include pediatric patients (ages 6-17) for the treatment of non-dystrophic myotonic disorders (NDM). The approval introduces two new dosage strengths, 62 mg and 83 mg, supplementing the existing 167 mg capsule. NaMuscla remains the only approved treatment for NDM symptoms in Europe, a rare condition with a prevalence of 1 in 100,000. This regulatory milestone supports Lupin's specialty portfolio growth in Europe, following its recent €190 million (approx. ₹2,000 Cr) expansion into Italy and Spain.
Confidence: HIGH
What changedLupin's NaMuscla, previously approved only for adults in Europe, now has marketing authorization for pediatric and adolescent patients with new lower-dose strengths.
Why it mattersThis strengthens Lupin's specialty drug pipeline in Europe, a key growth pillar intended to offset US generic price erosion. While the patient population is small (rare disease), specialty products typically command better pricing and margins than commoditized generics.
New Dosage Strengths: 62 mg and 83 mgDisease Prevalence: 1:100,000Recent EU Expansion Investment: €190 millionTTM Revenue: ₹27,958 CrOperating Profit Margin: 31.5%
📅 Short termThe news is sentimentally positive for the stock as it demonstrates progress in the high-margin specialty segment, though immediate revenue impact will be gradual due to reimbursement timelines.
📈 Long termSupports Lupin's structural shift toward complex generics and specialty medicines, which is critical for maintaining its 27% ROCE and 31.5% OPM in the face of global pricing pressures.
⚠ Risk flags
- Limited addressable market due to rare disease status
- National reimbursement hurdles in individual EU countries
- Execution risk in European market expansion
Key Highlights
EMA approval extends NaMuscla usage to children (6-11 years, min 20 kg) and adolescents (12-17 years).
Introduces two new dosage strengths of 62 mg and 83 mg to the existing 167 mg portfolio.
Targets Non-Dystrophic Myotonias (NDM), a rare disease with a prevalence of 1:100,000.
NaMuscla is currently the only licensed antimyotonic agent for this indication in Europe.
Approval follows the Pediatric Investigation Plan (PIP) requirements for European marketing.
👀 What to Watch
Watch for the timeline of national reimbursement and access processes across European markets, which will determine the actual revenue ramp-up for these new indications.
Lupin Receives Tentative U.S. FDA Approval for Enzalutamide Tablets (40mg to 160mg)
Lupin has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths. The 40 mg and 80 mg versions are bioequivalent to the reference drug Xtandi by Astellas, which is used in oncology. Lupin is also introducing 120 mg and 160 mg strengths to provide alternative dosing options for healthcare providers. This approval strengthens Lupin's specialty pipeline in the U.S. market, although a commercial launch will depend on final approval and patent timelines.
Key Highlights
Received tentative U.S. FDA approval for Enzalutamide Tablets in four strengths: 40 mg, 80 mg, 120 mg, and 160 mg.
The 40 mg and 80 mg strengths are bioequivalent to the reference listed drug (RLD) Xtandi Tablets of Astellas.
Lupin is offering unique 120 mg and 160 mg strengths to provide alternative dosing options for patients.
The product targets the oncology segment, expanding Lupin's complex generic portfolio in the United States.
👀 What to Watch
Investors should view this as a positive development for Lupin's U.S. pipeline, though they should monitor the timeline for final approval and patent expiry of the innovator drug for actual revenue impact.
Lupin Launches Azilsartan Medoxomil in US with 180-Day First-to-File Exclusivity
Lupin Limited has launched Azilsartan Medoxomil Tablets (40mg and 80mg) in the United States following US FDA approval. The company holds exclusive first-to-file status for this product, making it eligible for 180 days of generic drug exclusivity. The tablets are a generic version of Edarbi®, used for treating hypertension, and address a market valued at approximately USD 53.5 million in annual sales as of April 2026.
Key Highlights
Launched Azilsartan Medoxomil Tablets in 40mg and 80mg strengths in the U.S. market.
Granted exclusive first-to-file status with 180-day generic drug exclusivity.
Targets the U.S. hypertension market which has estimated annual sales of USD 53.5 million.
The product is a bioequivalent generic version of Azurity Pharmaceuticals' Edarbi®.
👀 What to Watch
Investors should monitor the revenue contribution from this launch over the next two quarters, as the 180-day exclusivity period typically yields higher margins before other generic competitors enter.
Lupin Collaborates with ERN to Launch Luforbec® Respiratory Inhaler in Spain
Lupin Limited has entered into a strategic collaboration with Spanish pharmaceutical firm LABORATORIOS ERN S.A. to launch Luforbec® (beclometasone/formoterol) in Spain. This fixed-dose combination inhaler is designed for the treatment of adult asthma and COPD, marking Lupin's continued expansion into the European respiratory market. The product has already seen successful introductions in the UK and Germany, and this partnership leverages ERN's local distribution network and manufacturing capacity of over 28 million units annually. This move strengthens Lupin's position in the high-value complex generics and respiratory therapy segments.
Key Highlights
Strategic partnership with LABORATORIOS ERN S.A. for the launch of Luforbec® 100/6 pMDI in Spain.
Targets the treatment of adult asthma and chronic obstructive pulmonary disease (COPD).
Follows successful product launches in the UK and Germany, expanding Lupin's EMEA footprint.
ERN brings a robust national reach in Spain, currently manufacturing more than 28 million units per year.
Reinforces Lupin's global commitment to the respiratory therapy area, a key growth driver for the company.
👀 What to Watch
Investors should monitor the market share gains in the Spanish respiratory segment as Lupin continues to scale its complex generic portfolio in Europe. This expansion supports long-term margin improvement through high-entry-barrier products.
Lupin Receives U.S. FDA Approval for Ranluspec (ranibizumab) Interchangeable Biosimilar
Lupin Limited has received U.S. FDA approval for Ranluspec, an interchangeable biosimilar referencing Genentech's Lucentis. This marks Lupin's second biosimilar approval in the U.S. market, significantly strengthening its complex biologics portfolio. Notably, Ranluspec is the only interchangeable ranibizumab approved in both vial and pre-filled syringe (PFS) formats. The approval covers both 0.3 mg and 0.5 mg strengths for treating conditions like wet age-related macular degeneration and diabetic retinopathy.
Key Highlights
Approved as an interchangeable biosimilar referencing Lucentis (Genentech) in the U.S. market.
Only interchangeable ranibizumab approved in both vials and pre-filled syringes (PFS).
Approval covers two dosage strengths: 0.3 mg (6 mg/mL) and 0.5 mg (10 mg/mL).
Represents Lupin's second U.S. biosimilar approval, expanding its presence in complex biologics.
Targets high-value indications including neovascular (wet) age-related macular degeneration and diabetic macular edema.
👀 What to Watch
Investors should view this as a major milestone that validates Lupin's R&D capabilities in the high-margin biosimilars space. Monitor the commercial launch and market penetration, as the interchangeable status and PFS format provide a competitive edge in the U.S. ophthalmic market.
Lupin and Natco Receive U.S. FDA Approval for Eribulin Mesylate Injection; $43.7M Market Size
Lupin Limited and its partner Natco Pharma have secured U.S. FDA approval for the Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection. This product is a bioequivalent to Eisai's Halaven® Injection, which is used to treat metastatic breast cancer and liposarcoma. According to IQVIA MAT April 2026 data, the reference drug had estimated annual sales of USD 43.7 million in the U.S. market. This approval marks another addition to Lupin's complex generics portfolio in the United States.
Key Highlights
Approval received for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
The product is bioequivalent to the reference listed drug Halaven® by Eisai, Inc.
Target indications include metastatic breast cancer and unresectable or metastatic liposarcoma.
The reference drug (Halaven®) had estimated annual U.S. sales of USD 43.7 million as of April 2026.
The approval was granted to alliance partner Natco Pharma for distribution by Lupin.
👀 What to Watch
Investors should monitor the launch timeline and market share gains in the oncology segment. While the $43.7 million market is relatively small for a company of Lupin's scale, it reinforces their capability in complex injectables and strengthens their U.S. generic pipeline.
Lupin Receives U.S. FDA Approval for Generic Sutab® with 180-Day Exclusivity
Lupin has received U.S. FDA approval for its generic version of Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, used for colonoscopy preparation. The company is the exclusive first-to-file for this product, making it eligible for 180 days of generic drug exclusivity. The reference drug, Sutab®, had estimated annual U.S. sales of USD 132.8 million as of March 2026. Production will be handled at Lupin's Nagpur facility, enhancing its high-margin generic portfolio in the U.S.
Key Highlights
Received U.S. FDA approval for generic Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets.
Granted exclusive first-to-file status with 180-day generic drug exclusivity.
Targeting a U.S. market size of approximately USD 132.8 million based on IQVIA MAT March 2026 data.
Manufacturing will be conducted at Lupin’s state-of-the-art facility in Nagpur, India.
👀 What to Watch
Investors should monitor the launch timeline as the 180-day exclusivity period provides a significant competitive advantage and higher margin potential. This approval reinforces Lupin's strong pipeline execution in the U.S. generic market.
Lupin Reports Positive Phase 1 Data for Cancer Drug LNP8701 at ASCO 2026
Lupin Limited has announced successful Phase 1a clinical trial results for LNP8701, a novel SOS1 inhibitor targeting metastatic solid tumors. The study, presented at the ASCO 2026 meeting, showed the drug was well-tolerated with a favorable safety and pharmacokinetic profile across all dosing levels. Preliminary efficacy was noted with two patients completing 12 cycles (1 year) of monotherapy and one patient completing 14 cycles with stable disease. The company is now advancing to Phase 1b trials in India to explore the drug's potential as both a monotherapy and in combination treatments.
Key Highlights
LNP8701 is an orally administered SOS1 inhibitor designed to block oncogenic signaling in solid tumors.
Two patients completed 12 cycles (1 year) of monotherapy, demonstrating long-term tolerability.
One patient achieved stable disease after 14 cycles of treatment in the first-in-human study.
The drug demonstrated a favorable safety profile across all tested dosing levels in Phase 1a.
Lupin plans to initiate Phase 1b trials in India to further evaluate efficacy and combination potential.
👀 What to Watch
Investors should monitor the progress of Phase 1b trials as this represents a significant step in Lupin's high-value oncology pipeline. While early-stage, successful data at a major forum like ASCO validates Lupin's R&D capabilities in novel drug discovery.
Lupin Shares Positive Phase 1 Data for Cancer Drug LNP8701 at ASCO 2026
Lupin Limited has presented Phase 1a clinical data for its novel SOS1 inhibitor, LNP8701, at the ASCO 2026 Annual Meeting. The study focused on safety and tolerability in patients with metastatic solid tumors, showing the drug is well-tolerated across all dosing levels. Key efficacy signals included two patients completing 12 cycles (one year) of treatment and one patient reaching 14 cycles with stable disease. These results support the advancement of the drug into Phase 1b trials in India to further explore its therapeutic potential.
Key Highlights
LNP8701 is a novel oral SOS1 inhibitor designed to block RAS activation in solid tumors
Two patients successfully completed 12 cycles (1 year) of LNP8701 monotherapy
One patient completed 14 cycles of treatment with stable disease observed
The drug was found to be safe and well-tolerated across all tested dosing levels in the Phase 1a study
Lupin is progressing to Phase 1b trials in India to evaluate efficacy as both monotherapy and combination therapy
👀 What to Watch
Investors should monitor the progress of the upcoming Phase 1b trials as a key milestone for Lupin's oncology pipeline. While these early results are promising, the drug is still in the early stages of the clinical development lifecycle.
Lupin Enters Chinese Market with NMPA Approval for Oseltamivir Phosphate Oral Suspension
Lupin has achieved a significant strategic milestone by receiving its first-ever product approval in China from the National Medical Products Administration (NMPA). The approval is for Oseltamivir Phosphate Oral Suspension (6 mg/mL), an antiviral used to treat and prevent Influenza A and B. This entry into the world's second-largest pharmaceutical market is supported by a partnership with Yabao Pharmaceuticals, a leader in China's pediatric medicine sector. This move marks the beginning of Lupin's commercial presence in China, focusing initially on the high-demand pediatric segment.
Key Highlights
Marks Lupin's first-ever product entry and regulatory approval in the Chinese pharmaceutical market.
Approval granted for Oseltamivir Phosphate Oral Suspension (6 mg/mL) for patients 2 weeks and older.
Strategic partnership formed with Yabao Pharmaceuticals for commercialization and market access in China.
Targets the significant pediatric market for Influenza treatment, expanding Lupin's global footprint beyond India and the U.S.
👀 What to Watch
Investors should view this as a long-term growth catalyst as it opens up a massive new geography for Lupin's generic portfolio. Monitor the commercial ramp-up and potential for further product filings in the Chinese market.
Lupin Debuts in Dow Jones Best-in-Class Indices 2026 with Industry-Leading 91/100 ESG Score
Lupin Limited has been included for the first time in the Dow Jones Best-in-Class (DJBIC) World and Emerging Markets Indices for 2026. This follows the company's industry-leading score of 91/100 in the S&P Global Corporate Sustainability Assessment 2025, where it ranked in the top 1% globally. Inclusion in these indices is a significant milestone that enhances the company's appeal to global institutional investors who prioritize ESG criteria. The recognition underscores Lupin's commitment to sustainable business practices and long-term value creation.
Key Highlights
Lupin debuted in both the DJBIC World Index and the DJBIC Emerging Markets Index for 2026.
Achieved an industry-leading score of 91/100 in the S&P Global Corporate Sustainability Assessment 2025.
Ranked among the top 1% of companies globally for sustainability performance.
The DJBIC World Index tracks the top 10% of the 2,500 largest global companies in the S&P Global BMI.
👀 What to Watch
This inclusion is likely to increase interest from global ESG-focused institutional investors, potentially supporting the stock's valuation. Long-term investors should see this as a validation of the company's governance and sustainability standards.
Lupin Receives US FDA Tentative Approval for Revefenacin Inhalation Solution ($260M Market)
Lupin Limited has secured tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Revefenacin Inhalation Solution, 175 mcg/3 mL. This product is a bioequivalent version of Mylan’s Yupelri®, which is used for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The reference drug had estimated annual sales of USD 260.7 million in the U.S. market as of March 2026. This approval strengthens Lupin's complex respiratory portfolio, although a tentative approval indicates the company must wait for patent or exclusivity expirations before a commercial launch.
Key Highlights
Received tentative U.S. FDA approval for Revefenacin Inhalation Solution (175 mcg/3 mL)
Targets the U.S. COPD treatment market with an estimated annual value of USD 260.7 million
Product is bioequivalent to the reference listed drug Yupelri® by Mylan
Strengthens Lupin's presence in the high-entry-barrier respiratory therapy segment
Adds to Lupin's global portfolio across 100+ markets and 15 manufacturing sites
👀 What to Watch
Investors should monitor for the transition from tentative to final approval, which will trigger the commercial launch and revenue contribution. This development reinforces Lupin's strength in complex generics and respiratory products, supporting long-term growth in the U.S. market.
Lupin Launches Third Atharv Ability Neuro-Rehabilitation Center in Delhi
Lupin Limited has expanded its specialized healthcare footprint by inaugurating its third Atharv Ability neuro-rehabilitation center in Delhi. This follows the successful establishment of centers in Mumbai (2023) and Hyderabad (2024), marking a strategic push into high-value multidisciplinary care. The facility utilizes advanced robotics and AI-based systems to treat complex conditions like stroke and Parkinson's. This expansion demonstrates Lupin's commitment to diversifying its revenue streams beyond traditional pharmaceutical manufacturing into specialized medical services.
Key Highlights
Inaugurated the third Atharv Ability center in Delhi, expanding from Mumbai (2023) and Hyderabad (2024) locations.
Facility provides specialized care for stroke, traumatic brain injury, spinal cord injury, and Parkinson’s disease.
Incorporates advanced technology including end-effector robotics for gait training and AI-based postural-control systems.
Offers multidisciplinary therapies spanning neuro-physiotherapy, occupational, speech, and virtual-reality-based rehabilitation.
Strategic move to address the limited availability of integrated, high-quality neuro-rehabilitation in North India.
👀 What to Watch
Investors should monitor the growth of Lupin's service-oriented subsidiaries like Atharv Ability as they represent a higher-margin diversification strategy. While currently a small part of total revenue, successful scaling of these centers could improve long-term valuation multiples.
Lupin Q4 FY26: Record Revenue of ₹7,475 Cr and 68% EBITDA Growth; US Sales Hit $1.3B in FY26
Lupin reported a stellar Q4 FY26 with revenue growing 32% YoY to ₹7,475 crores and EBITDA margins expanding significantly to 29.7%. The US business was a major driver, achieving $1.3 billion in annual sales (+40% YoY) fueled by complex generics like Risperdal Consta and Tolvaptan. The India prescription business also outperformed the market, growing 14.5% in Q4, with chronic therapies now making up 66% of the mix. Management has guided for high-single digit revenue growth and approximately 25% margins for FY27.
Key Highlights
Q4 FY26 Revenue rose 32% YoY to ₹7,475 crores, marking the 15th consecutive quarter of growth.
US business achieved record annual sales of $1.318 billion, a 40% YoY increase in constant currency terms.
EBITDA for the quarter grew 68% YoY to ₹2,171 crores with margins improving by 590 bps to 29.7%.
India prescription business grew 14.5% YoY in Q4, outperforming the Indian Pharmaceutical Market (IPM) by 1.3x.
Management targets launching 50+ products in the US over the next three years, including 4 biosimilars and 10 exclusive first-to-files.
👀 What to Watch
Investors should favor the strong margin expansion and US growth momentum, though the FY27 margin guidance of 25% suggests a normalization from the current peak. Monitor the successful launch of the biosimilar pipeline and the integration of the VISUfarma acquisition.
Lupin Receives US FDA Approval for Famotidine Injection; Market Size USD 8.7 Million
Lupin has secured US FDA approval for its Abbreviated New Drug Application for Famotidine Injection, a generic version of Pepcid. The injection is indicated for treating ulcers and GERD in patients unable to take oral medications. The product will be manufactured at Lupin's Nagpur facility in India. According to IQVIA MAT March 2026 data, the product has an estimated annual US market size of USD 8.7 million.
Key Highlights
Received US FDA approval for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL) Single-Dose Vials.
The product is bioequivalent to the reference listed drug Pepcid Injection by Merck Sharp & Dohme Corp.
Estimated annual sales for Famotidine Injection in the U.S. were USD 8.7 million as of March 2026.
Manufacturing will be conducted at Lupin’s Nagpur facility in India.
👀 What to Watch
Investors should view this as a positive incremental addition to Lupin's US generic portfolio. While the market size is modest, it demonstrates consistent regulatory execution and manufacturing compliance.
Lupin Q4 FY26 Net Profit Surges 89% YoY to ₹1,460 Cr; US Sales Grow 55%
Lupin reported a stellar performance for Q4 FY26, with net sales growing 33% YoY to ₹7,392 crore and net income jumping 89% to ₹1,460 crore. The growth was primarily driven by the North American market, which saw a 55% YoY revenue increase, and a strong 12% growth in the domestic India business. EBITDA margins expanded significantly to 29.4% from 23.2% a year ago, reflecting improved operational efficiency. The company also achieved a net cash position with a net debt-to-equity ratio of -0.21.
Key Highlights
Q4 FY26 Net Income rose 89% YoY to ₹14,604 mn, while EBITDA grew 68% to ₹21,711 mn.
North America sales surged 55% YoY to ₹35,145 mn, driven by new product launches and complex generics.
India business grew 12% YoY to ₹19,082 mn, outperforming the market in Cardiology and Respiratory segments.
EBITDA margins improved to 29.4% in Q4 FY26 compared to 23.2% in Q4 FY25.
Company turned net cash positive with a net debt-to-equity ratio of -0.21 as of March 31, 2026.
👀 What to Watch
Investors should view this as a strong performance, particularly the massive margin expansion and US market recovery. The focus on complex generics and biosimilars provides a healthy long-term outlook.
Lupin Q4 FY26 PAT Jumps 88% YoY to ₹14,687 Mn; EBITDA Margins Expand to 35.5%
Lupin reported a stellar performance for Q4 FY2026, with consolidated revenue growing 32.9% YoY to ₹73,919 Mn. Net profit for the quarter surged 87.7% YoY to ₹14,687 Mn, driven by robust growth in the US market (up 56.9%) and significant margin expansion. The Board recommended a high dividend of 900%, reflecting strong cash flows and a net cash position of ₹46,358 Mn. Full-year FY26 revenue and PAT also showed strong double-digit growth of 23.9% and 62.0% respectively.
Key Highlights
Q4 FY26 EBITDA surged 90.6% YoY to ₹26,263 Mn with margins expanding by 1070 bps to 35.5%.
US sales grew 56.9% YoY to ₹33,987 Mn, now accounting for 46% of total global sales.
India formulation sales grew 14.5% in Q4, maintaining Lupin's position as the 8th largest player in the domestic market.
The company turned net debt-free with a net cash balance of ₹46,358 Mn as of March 31, 2026.
Recommended a dividend of 900% for the fiscal year based on a strong long-term outlook.
👀 What to Watch
The significant margin expansion and robust US growth make Lupin a strong pick in the pharma sector. Investors should maintain their positions as the company leverages its net cash status for future growth and complex generic launches.
Lupin Recommends ₹18 Dividend; FY26 Net Profit Jumps 60% to ₹63,666 Million
Lupin Limited has recommended a final dividend of ₹18 per share for the financial year ended March 31, 2026, representing a 900% payout on its face value. The company reported a robust annual performance with total revenue from operations growing 15% to ₹195,126.6 million. Net profit for the year saw a significant surge of 60.2%, reaching ₹63,665.6 million compared to ₹39,729.6 million in FY25. This growth was bolstered by strong operational margins and a net exceptional gain of ₹4,065.7 million from business divestments.
Key Highlights
Recommended a final dividend of ₹18 per equity share of face value ₹2 each.
Annual revenue from operations increased 15% YoY to ₹195,126.6 million.
Net profit after tax surged 60.2% YoY to ₹63,665.6 million for FY26.
Basic Earnings Per Share (EPS) rose significantly to ₹139.38 from ₹87.10 in the previous year.
Recorded a net exceptional gain of ₹4,065.7 million, primarily driven by the divestment of OTC and API R&D businesses.
👀 What to Watch
Investors should consider the strong earnings growth and high dividend payout as a positive indicator of the company's financial health. The stock remains attractive for dividend-seeking investors, though one should monitor the ongoing legal settlements mentioned in the notes.
Lupin Q4 FY26 Net Profit Jumps 67% to ₹2,164 Cr; Announces ₹18 Dividend
Lupin reported a robust Q4 FY26 with standalone revenue increasing 16.7% YoY to ₹5,234.6 crore. Net profit for the quarter surged to ₹2,163.7 crore, bolstered by exceptional gains from divestments of its OTC and API R&D units. For the full fiscal year 2026, the company recorded a total revenue of ₹19,512.7 crore and a net profit of ₹6,366.6 crore. The board has rewarded shareholders with a significant final dividend of ₹18 per share, representing a 900% payout on face value.
Key Highlights
Q4 FY26 standalone revenue grew 16.7% YoY to ₹5,234.6 crore from ₹4,485.7 crore.
Net profit for the quarter rose to ₹2,163.7 crore compared to ₹1,291.4 crore in Q4 FY25.
Recommended a final dividend of ₹18 per equity share (900% of face value) for FY26.
Full-year FY26 net profit increased 60% to ₹6,366.6 crore against ₹3,973.0 crore in FY25.
Exceptional items include a ₹659 crore gain from the divestment of the OTC business unit.
👀 What to Watch
The strong financial performance and high dividend yield make Lupin an attractive hold for long-term investors. Monitor the impact of ongoing US antitrust litigation settlements on future cash flows.
Lupin Receives US FDA Approval for Glycerol Phenylbutyrate Oral Liquid ($337M Market)
Lupin Limited has secured US FDA approval for its generic version of Ravicti® (Glycerol Phenylbutyrate Oral Liquid, 1.1 g/mL). The drug is used for the chronic management of urea cycle disorders (UCDs) in patients who cannot be managed by diet alone. According to IQVIA MAT December 2025 data, the reference product had annual sales of approximately USD 337 million in the United States. This approval marks a significant addition to Lupin's complex generic portfolio in the US market.
Key Highlights
Received US FDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL.
Product is bioequivalent to the reference drug Ravicti® from Horizon Therapeutics.
Target market size for the product is estimated at USD 337 million based on 2025 sales data.
Indicated for patients with urea cycle disorders (UCDs) requiring chronic management.
Strengthens Lupin's position in the US generic formulations and specialty therapy segments.
👀 What to Watch
Investors should monitor the commercial launch timeline and Lupin's ability to capture market share in this $337 million niche segment. This approval supports the company's growth outlook for its US business in the 2026-27 fiscal period.
